title: Imatinib in neurofibromatosis type 2.
abstract: A 30-year-old man with a 10-year history of neurofibromatosis type 2 (NF-2) and minimal hearing in his left ear, presented with rapidly progressive disease and risk of total hearing loss. He was started on imatinib and achieved stable disease for 4 months, after which the drug was ceased due to toxicity. He was then treated with bevacizumab for 8 months with a best response of stable disease.
authors.affiliation: Department of Medical Oncology, Liverpool Hospital, Liverpool, New South Wales, Australia.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Lim
authors.forename: Paul
authors.initials: P
authors.lastname: de Souza
mesh_terms: D000328:Adult; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D016518:Neurofibromatosis 2 / Q000188:drug therapy*; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate